06 September 2018
A new report by visiongain forecasts the overall world market for Alzheimer’s disease therapeutics and diagnostics will reach $11.5bn in 2020. That revenue prediction and others appear in Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies, published in May 2016. Visiongain is a business information publisher and consultancy in London, UK. It produces research, data and analysis to help organisations understand markets and their potentials.
This study also analyses qualitative issues affecting the Alzheimer’s disease therapeutics and diagnostics drug market from 2015, with recent events, opinions and predictions. Economic impact, clinical trial guidelines, new research development, and many other forces are discussed. The result is a quantitative and qualitative analysis of the Alzheimer’s disease therapeutics and diagnostics market, showing commercial potentials of those drugs and diagnostics from 2016 to 2026.
From 2015, new therapies and high medical needs encourage investments, developments, wider treatment and higher sales from upcoming drugs. The new study discusses commercial potentials of top leading pipeline drugs and diagnostics tests. That investigation gives multilevel revenue forecasting to 2026.
Shruti Tayal, a pharmaceutical industry analyst in visiongain, said: “The Alzheimer’s disease therapeutics market has been stagnant over the last few years, with major disappointments in late stage clinical trials. However, at present there are many drugs in Phase III trial, hoping for approval. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. There is an increasing drive towards finding the underlying cause of Alzheimer’s disease to develop a drug which can change the course of history. Since the older population is increasing in the world, the cost incurred by treatment and care for Alzheimer’s has become a global burden.”
The fastest growth will continue to be seen in the emerging economies, where there is still high growth in revenues of Alzheimer’s drugs that have gone off-patent in the majority of developed markets. Many leading Alzheimer’s therapeutic companies are investing aggressively to increase their presence in the country and this trend is set to continue with the demand from a rapidly ageing population.
That updated investigation shows revenue forecasts to 2026 at overall world market, submarket, product and national level. It has two submarkets:
• Alzheimer’s drug market
• Alzheimer’s diagnostics market
Those analyses forecast the revenues of 6 leading Alzheimer’s drugs in the market and in the pipeline from 2016 to 2026, which are Namenda, Aricept, Exelon, Solanezumab, Gantenerumab and MK-8931. The new survey also discusses Alzheimer’s drug candidates in clinical trials, examining research and development. The market is expected to grow in the second half of the forecast period.
That report includes trends and forecast revenues in leading national markets. Countries and regions analysed are the US, the EU (Germany, France, the UK, Spain, Italy), Japan, BRIC (Brazil, Russia, India and China) and the Rest of the World (RoW). That study also contains three interviews with other authorities on Alzheimer’s disease.
Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2016-2026: Opportunities for Leading Companies adds to visiongain’s reports on industries and markets in healthcare. Those studies analyse pharmaceuticals, medical devices, diagnostics and contract services, showing their technological, clinical and commercial potentials.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.